Trilogy Capital Inc. Humacyte, Inc. Transaction History
Trilogy Capital Inc.
- $1.87 Billion
- Q1 2025
A detailed history of Trilogy Capital Inc. transactions in Humacyte, Inc. stock. As of the latest transaction made, Trilogy Capital Inc. holds 169,800 shares of HUMA stock, worth $421,104. This represents 0.02% of its overall portfolio holdings.
Number of Shares
169,800
Previous 83,500
103.35%
Holding current value
$421,104
Previous $421,000
31.12%
% of portfolio
0.02%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding HUMA
# of Institutions
181Shares Held
59.9MCall Options Held
1.05MPut Options Held
877K-
Black Rock Inc. New York, NY7.14MShares$17.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.6MShares$16.4 Million0.0% of portfolio
-
State Street Corp Boston, MA4.27MShares$10.6 Million0.0% of portfolio
-
Heights Capital Management, Inc San Francisco, CA4.03MShares$9.98 Million3.22% of portfolio
-
Woodline Partners LP San Francisco, CA3.95MShares$9.8 Million0.05% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $255M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...